IDEXX Laboratories, Inc. $IDXX Shares Acquired by World Investment Advisors

Posted by Brian Himes on Jun 22nd, 2026

World Investment Advisors increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 126.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,902 shares of the company’s stock after purchasing an additional 1,061 shares during the quarter. World Investment Advisors’ holdings in IDEXX Laboratories were worth $1,287,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its position in IDEXX Laboratories by 2.5% in the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after acquiring an additional 15 shares during the period. Harbour Investments Inc. raised its position in IDEXX Laboratories by 13.3% in the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares during the period. CWA Asset Management Group LLC lifted its stake in shares of IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after purchasing an additional 17 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in shares of IDEXX Laboratories by 11.5% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after purchasing an additional 18 shares during the last quarter. Finally, Rockland Trust Co. grew its holdings in shares of IDEXX Laboratories by 4.4% during the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after purchasing an additional 18 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

IDXX stock opened at $562.09 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $44.34 billion, a PE ratio of 41.39, a P/E/G ratio of 3.07 and a beta of 1.56. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The business’s fifty day moving average price is $561.66 and its 200 day moving average price is $620.14.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business posted $2.91 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IDXX. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Finally, UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $751.00.

View Our Latest Report on IDXX

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.